Cingulate Inc. Share Price
CINGCingulate Inc. Stock Performance
Open $6.73 | Prev. Close $7.53 | Circuit Range N/A |
Day Range $6.71 - $7.74 | Year Range $3.23 - $7.74 | Volume 6,409 |
Average Traded $7.42 |
Cingulate Inc. Share Price Chart
About Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Feb-26 | $6.73 | $7.74 | +19.26% |
05-Feb-26 | $6.94 | $6.49 | +4.01% |
04-Feb-26 | $6.24 | $6.24 | +0.16% |
03-Feb-26 | $6.03 | $6.23 | +1.96% |
02-Feb-26 | $5.87 | $6.11 | +6.82% |
30-Jan-26 | $5.58 | $5.72 | -0.17% |
29-Jan-26 | $5.61 | $5.73 | -2.39% |